NASDAQ · BNTX
BioNTech SE American Depositary Share
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BNTX: Nov 03, 2026
BioNTech SE American Depositary Share is expected to report earnings on 11/03/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $0.85. The reported EPS for the same quarter last year was $-0.14.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.85 | $1.12 | $0.43 | 3 |
| Dec 2026 | $-1.63 | $-1.32 | $-2.07 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Fintel · RTTNews · The Motley Fool- Zacks · Oct 29, 10:58 AM EDTBMY Q3 Earnings Tops Estimates, Higher Charges Weigh on OutlookBristol Myers tops Q3 earnings and revenue estimates as Growth Portfolio sales and Eliquis demand drive growth, but higher IPRD charges prompt a cut to 2026 EPS guidance.
- Zacks · Oct 28, 10:26 AM EDTPfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy?Pfizer heads into Q3 earnings with strong drug sales and an attractive valuation, but declining COVID revenues and looming patent expirations pose challenges.
- Fintel · Oct 26, 8:32 AM EDTBioNTech SE and Bristol Myers Squibb Report Phase 2 Data for Pumitamig in Advanced NSCLCBioNTech SE and Bristol Myers Squibb Company announced first data from the global Phase 2 ROSETTA Lung-107 clinical trial evaluating pumitamig, an investigational PD-L1xVEGF-A bispecific immunomodulator, in combination with docetaxel in patients with metastatic non-small cell lun
- Fintel · Oct 26, 7:42 AM EDTBioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical TrialBioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase 3 clinical trial (NCT06018337) met its primary endpoint demonstrating a statistically signif
- RTTNews · Oct 26, 6:08 AM EDTBioNTech, DualityBio Breast Cancer Drug Meets Phase 3 Trial Goal But Shows Higher Lung Disease Rate(RTTNews) – On Monday, BioNTech (BNTX) and DualityBiologics, subsidiary of Duality Biotherapeutics (9606.HK) said trastuzumab pamirtecan met the primary endpoint in the Phase 3 DYNASTY-Breast02 trial, showing a statistically significant but modest improvement in progression-free
- RTTNews · Oct 26, 4:48 AM EDTBioNTech, Bristol Myers' Pumitamig Shows 36.7% Response Rate In Phase 2 NSCLC Trial(RTTNews) – BioNTech SE (BNTX) and Bristol Myers Squibb Company (BMY) announced first data from the Phase 2 ROSETTA Lung-107 clinical trial evaluating pumitamig plus docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after firs
- Fintel · Oct 22, 12:24 PM EDTBioNTech SE Announces Collaboration with Gilead for Phase 3 Trial of PumitamigBioNTech SE announced a clinical trial collaboration and supply agreement with Gilead Sciences Inc. to evaluate pumitamig in combination with the TROP2-directed antibody-drug conjugate sacituzumab govitecan as first-line treatment for patients with locally advanced or metastatic
- RTTNews · Oct 22, 7:18 AM EDTBioNTech Expands Phase 3 Breast Cancer Trial Through Collaboration With Gilead(RTTNews) – BioNTech SE (BNTX) has entered a clinical trial collaboration with Gilead Sciences (GILD) to evaluate the investigational drug Pumitamig in combination with Trodelvy (sacituzumab govitecan) as a first-line treatment for patients with advanced triple-negative breast ca
- Zacks · Oct 21, 8:25 AM EDTModerna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?MRNA expands beyond COVID-19 with new RSV, flu and combination vaccines, but fierce competition could challenge its efforts to diversify revenue.
- Zacks · Oct 19, 9:25 AM EDTPfizer's Non-Oncology Performance in Q3: Driving Factors to WatchPfizer's Q3 results will shed light on its non-oncology portfolio, as demand trends, pricing pressure and vaccine sales shape performance across key therapies.
- The Motley Fool · Oct 18, 2:52 PM EDTAnother BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?BioNTech needs new products to kickstart sales and earnings growth.
- The Motley Fool · Oct 17, 12:43 PM EDTMove Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer PipelineA 16.6 billion euro cash balance gives BioNTech room to fund trials, partnerships, and a $1 billion share repurchase program.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for BioNTech SE American Depositary Share from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.